Summit Therapeutics Partners with AstraZeneca in a $2 Billion Cancer Drug Collaboration.
Oct 01, 2026
Contract Type
partnership
MiamiBiotechnologyHealth CareTherapeutics
Description
Summit Therapeutics has entered into a $2 billion equity and collaboration agreement with AstraZeneca to advance its cancer drug ivonescimab. This partnership marks a significant investment by AstraZeneca, aimed at enhancing the clinical programs of ivonescimab.
Company Information
Company
Summit Therapeutics
Location
Miami, Florida, United States
About
Summit Therapeutics’ mission is to resolve serious, unmet medical needs for the betterment of overall human health.